Compare Incyte Corporation (INCY) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Toyota Motor Corp — how do they compare? Incyte Corporation trades at $117.95 (market cap $23.11B), while Toyota Motor Corp trades at $181.21 (market cap $212.22B). The key difference: Toyota Motor Corp is far larger — about 9.2× Incyte Corporation's market cap, and Toyota Motor Corp pays a 3.51% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TM | |
|---|---|---|
Market Cap | $23.11B | $212.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $248.29 |
52-Week Low | $67.38 | $166.50 |
Enterprise Value | $19.13B | $376.42B |
Dividend Yield | — | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Toyota Motor (TM) trades at $178.53, up 0.52% with neutral technical signals. The stock shows strong fundamentals with a low P/E of 9.73 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion announced July 6, 2026 (Reuters), signaling growth commitment. Cash flow trends show a 2025 dip but project recovery in 2026 with operating cash flow of $5.47 trillion.
Outlook is cautiously positive given undervaluation and hybrid vehicle demand, but risks include rising debt-to-asset ratios (41.29% in 2025) and margin pressure. Analyst consensus is mixed with 37.5% buy ratings, suggesting potential upside if execution aligns with expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
